Ignite Creation Date:
2025-12-24 @ 11:50 AM
Ignite Modification Date:
2025-12-24 @ 11:50 AM
Study NCT ID:
NCT01704261
Status:
COMPLETED
Last Update Posted:
2018-09-10
First Post:
2012-10-08
Is Possible Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-10-18
Start Date Type:
ACTUAL
Primary Completion Date:
2014-12-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-12-23
Completion Date Type:
ACTUAL
First Submit Date:
2012-10-08
First Submit QC Date:
None
Study First Post Date:
2012-10-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2015-10-23
Results First Submit QC Date:
None
Results First Post Date:
2015-11-25
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-08-09
Last Update Post Date:
2018-09-10
Last Update Post Date Type:
ACTUAL